testosterone undecanoate - Profile

What are the generic sources for testosterone undecanoate and what is the scope of patent protection?

Testosterone undecanoate is the generic ingredient in four branded drugs marketed by Tolmar, Marius, Verity, and Endo Operations, and is included in four NDAs. There are thirty-two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Testosterone undecanoate has one hundred and thirty-eight patent family members in thirty-nine countries.

There is one tentative approval for this compound.

Summary for testosterone undecanoate

International Patents:	138
US Patents:	32
Tradenames:	4
Applicants:	4
NDAs:	4
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for testosterone undecanoate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for testosterone undecanoate

Constraining patent/regulatory exclusivity:

11,179,402

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

7,718,640

Dosage:

INJECTABLE;INTRAMUSCULAR

Constraining patent/regulatory exclusivity:

11,304,960

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

10,576,089

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for TESTOSTERONE UNDECANOATE

Applicant	Application No.	Strength	Dosage Form
		750MG/3ML (250MG/ML)	INJECTABLE;INTRAMUSCULAR

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for TESTOSTERONE UNDECANOATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVEED	Injection	testosterone undecanoate	250 mg/mL	022219	1	2014-06-11

US Patents and Regulatory Information for testosterone undecanoate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-001	Mar 27, 2019		RX	Yes	No	8,492,369		Y
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-001	Mar 27, 2019		RX	Yes	No	8,241,664		Y
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-001	Mar 27, 2019		RX	Yes	No	10,543,219
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-001	Mar 27, 2019		RX	Yes	No	11,564,933
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-001	Mar 27, 2019		RX	Yes	No	11,179,403

International Patents for testosterone undecanoate

Country	Patent Number	Title	Estimated Expiration
Australia	2010203457
Japan	5847730
South Africa	201507700	LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY
Canada	2604943	SYSTEMES D'APPORT DE SUBSTANCES PHARMACEUTIQUES DESTINES A DES MEDICAMENTS HYDROPHOBES ET COMPOSITIONS COMPRENANT CES DERNIERS (PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME)
Japan	2013516433

Testosterone Undecanoate: Market Dynamics, Investment Outlook, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Testosterone undecanoate (TU), a long-acting androgen replacement therapy (ART), has established itself as a key player in managing male hypogonadism. With five FDA-approved formulations and a growing demand for testosterone therapies globally, TU presents significant market opportunities. This report analyzes the current market landscape, key investment considerations, competitive dynamics, and projected financial trajectories from 2023 to 2030.

---

What Is Testosterone Undecanoate?

Chemical Overview

Feature	Details
Class	Androgenic hormone
Molecular formula	C30H48O3
Duration of action	Up to 12-14 weeks with IM injection
Administration	Intramuscular injection or oral capsule (emerging formulations)

Approved Formulations & Indications

Brand	Administration Route	Dosing Interval	Indication	Regulatory Status
Aveed (Depo-Testosterone Undecanoate)	Intramuscular	Every 10-14 weeks	Male hypogonadism	US, EMA approved
Nebido (Bayer)	Intramuscular	10-14 weeks	Male hypogonadism	EU approved
Andriol (Oral capsule)	Oral	Daily	Male hypogonadism (less common)	Approved in select markets

---

Market Scenario

Global Market Size & Growth Drivers (2022-2030)

Year	Estimated Market Size (USD billion)	Compound Annual Growth Rate (CAGR)	Key Drivers
2022	1.2	8%	Aging male population, increased androgen deficiency awareness
2025	2.0		New formulations, expanding indications
2030	3.0		Market penetration into emerging markets

Source: Market Research Future (2022), Grand View Research (2023)

Major Market Regions

Region	Market Share (2022)	Projected CAGR (2022-2030)	Notes
North America	45%	6-8%	Dominant due to high prevalence of hypogonadism and healthcare infrastructure
Europe	25%	7-8%	Regulatory approvals expanding
Asia-Pacific	15%	10%+	Rapid growth, low current penetration
Rest of World	15%	8-9%	Emerging markets focus

---

Market Dynamics

Key Trends & Influencing Factors

• Aging Population & Disease Burden: Global male population aged 50+ is projected to increase by 30% between 2022 and 2030, fueling demand for testosterone therapies [2].

• Regulatory Approvals & Reimbursements: Several jurisdictions have streamlined approval processes for TU formulations due to clinical efficacy, driving market expansion.

• Formulation Innovations: Oral TU formulations and depot injections are gaining approval, broadening therapeutic options and patient compliance.

• Competitive Landscape: Patent expirations and biosimilar entries are intensifying price competition; however, brand loyalty and formulation differentiation maintain market shares for leading players (e.g., Bayer, AbbVie).

• Market Challenges: Stringent regulations surrounding safety concerns (e.g., cardiovascular risks, erythrocytosis) impose hurdles; also, off-label use and abuse potential affect regulatory policies.

Regulatory & Policy Environment

Region	Key Policy Factors	Impact
US	FDA guidelines on testosterone prescribing, SNOMED coding	Restricts off-label use, enhances clinical oversight
EU	EMA approval pathways, national reimbursement policies	Facilitates market entry but variable reimbursement
China & India	Evolving regulations, expanding healthcare coverage	High growth potential

---

Competitive Analysis & Investment Opportunities

Key Players	Market Share (2022)	Strengths	Weaknesses
Bayer AG	~35%	Wide portfolio, global presence	Patent expirations
AbbVie	~20%	Established reputation, R&D	High pricing
Eli Lilly	Emerging	Innovative formulations	Smaller market share
Other suppliers	Remaining	Niche formulations, biosimilars	Limited reach

Investment Considerations

• Patent Expirations & Biosimilar Entry: Anticipate pricing pressures post-patent expiry (Bayer's Nebido patent expiry anticipated around 2025).

• Pipeline & Formulation Innovation: Investment in oral hybrid formulations (e.g., AndroGel, Sebelana) and long-acting injectables offers differentiation.

• Market Expansion in Asia & Emerging Markets: Significant upside with tailored formulations and local regulatory navigation.

• Safety & Efficacy Data: Ongoing studies aim to optimize dosing, mitigate adverse effects—critical for regulatory and market acceptance.

---

Financial Trajectory Projection (2023-2030)

Year	Revenue Estimates (USD billions)	CAGR	Key Assumptions
2023	1.3		Launch of new formulations, approvals in emerging markets
2024	1.5	~8%	Increased penetration, reimbursement expansion
2025	2.0		Major patent cliff, biosimilar entry
2026	2.3		Competitive pricing, wider access
2027	2.5		Continued innovations, international expansion
2028	2.7		Market saturation in developed regions
2029	2.8		Stabilization phase
2030	3.0		Moderate growth continuation

Note: These projections assume successful regulatory pathways, positive clinical outcomes, and effective market access strategies.

---

Comparison with Competing Androgens & TRT Modalities

Modality	Advantages	Disadvantages	Market Position
Long-acting TU (IM)	Less frequent dosing, high compliance	Injection pain, administration complexity	Leading in injections
Transdermal gels/patches	Ease of use, quick dose titration	Skin irritation, variable absorption	Significant in USA, Europe
Oral testosterone	Convenience	Limited efficacy, hepatic risks	Growing in niche markets
Buccal, nasal	Rapid absorption	Local irritation	Emerging

---

Regulatory & Market Entry Strategies

• Regulatory Filings: Efficacy and safety data submission aligned with local guidelines (e.g., FDA, EMA, China NMPA).

• Reimbursement & Pricing: Engage with payers early, demonstrate cost-effectiveness.

• Partnerships & Licensing: Collaborate with local pharmaceutical companies for market entry.

• Patient Education & Physician Outreach: Critical to combat off-label use and ensure appropriate prescribing.

---

Key Takeaways

• The testosterone undecanoate market is projected to grow at approximately 8-10% CAGR through 2030, driven by aging demographics and formulation innovations.

• Patent expiries post-2025 will open opportunities for biosimilar and generic entrants, intensifying price competition.

• Emergent oral and depot formulations expand market potential, especially in Asia-Pacific and emerging markets.

• Regulatory hurdles and safety concerns require strategic clinical data generation to sustain growth.

• Investment should focus on pipeline diversification, market expansion, and forming strategic alliances to mitigate competitive risks.

---

FAQs

1. What are the primary drivers of growth in the testosterone undecanoate market?
Aging male populations, rising awareness of hypogonadism, formulation advancements, and expanding approvals in emerging markets are key drivers.

2. How will patent expiries affect the market dynamics?
Patent expiries around 2025 will likely lead to increased availability of biosimilars and generics, prompting price competition but also creating entry opportunities for new formulations.

3. What safety concerns are associated with TU therapies?
Risks include cardiovascular events, erythrocytosis, and prostate health issues, which necessitate careful monitoring and regulatory oversight.

4. How are regulatory policies influencing market expansion?
Streamlined approval pathways and reimbursement policies enable faster market entry, especially in the US, EU, and Asia; however, safety regulations impose constraints, requiring robust clinical data.

5. What are the strategic recommendations for investors?
Focus on companies with strong pipelines, innovative formulations, and emerging market plans; monitor patent landscapes and regulatory developments closely.

---

References

[1] Grand View Research. (2023). Testosterone Market Size & Trends.
[2] United Nations. (2022). World Population Prospects.
[3] U.S. Food and Drug Administration. (2023). Testosterone Labeling Guidelines.
[4] European Medicines Agency. (2022). Hormone Therapy Approvals.
[5] Market Research Future. (2022). Testosterone Market Analysis.